Refine your search
1,131 results found
Fenwick & West LLP | USA | 19 Jan 2023
2022 Corporate Governance Practices and Trends
Differences in their stage of development, including the relative importance placed on various business objectives (for example, focus on growth and…
Taylor Wessing | United Kingdom | 18 Jan 2023
Global pharma groups Eli Lilly and AbbVie withdraw from UK’s branded medicines voluntary scheme
The Associate of the British Pharmaceutical Industry (ABPI) announced on 16 January that two global pharmaceutical companies, Eli Lilly and AbbVie…
Pearce IP | Australia | 16 Jan 2023
BioBlast® w/e 13 Jan 23: Alvotech’s golimumab, Alvotech and Fuji commercialisation partnership, Dong-A ST’s ustekinumab, Coherus and Klinge’s deal for US aflibercept, Boan Biotech and CP Qingdao denosumab deal, Rani and Celltrion’s oral ustekinumab biosimilar
Korea Biomedical Review reported that Dong-A STl has published the results of its global Ph III trials of DMB-3115 (biosimilar ustekinumab). Dong-A…
Gowling WLG | Canada | 16 Jan 2023
Life sciences in Canada: 2022 year in review highlights
Canadian Courts issued many life sciences decisions in 2022. This article summarizes a number of the more notable court decisions, as well as other…
Venable LLP | USA | 12 Jan 2023
Venable’s BiologicsHQ Monthly Injection - December 2022
BiologicsHQ's "Spotlight On" product dashboards provide, at a glance, an overview of the status of U.S. patent proceedings. The dashboards concerning…
Smart & Biggar | Canada, Global | 12 Jan 2023
Canadian Patent law 2022: A Year in Review
2022 was an active year in Canadian patent law. Claim fees were introduced for the first time; changes were made to regulations providing remedies for…
Pearce IP | Australia, Canada | 9 Jan 2023
BioBlast® w/e 06 January 2023: Biocon insulin, Alvotech ustekinumab, Celltrion Vegzelma™ (bevacizumab), Lannett’s biosimilar insulin products, Alteogen and Celltrion agreement, Samsung Bioepis adalimumab interchangeability, Amgen’s adalimumab, Ontario biosimilar switching program, Hikma and Celltrion bevacizumab agreement, Samsung Bioepis Hadlima® approval, Keytruda® trials, Celltrion’s subcutaneous infliximab, Alvotech adalimumab, Dr Reddy’s tocilizumab, ustekinumab biosimilar
Biocon announced that it has received a complete response letter (CRL) from the FDA in relation to its insulin-r product. Biocon reported that the…
K&L Gates LLP | USA | 6 Jan 2023
Perrigo Co. v. AbbVie Inc. - Third Circuit Holds Mutual Release Bars Generic Drug Company's Antitrust Claim Alleging that "Sham" Patent Infringement Litigation Delayed Generic Drug Launch
On 21 July 2022, the Third Circuit in Perrigo Co. v. AbbVie Inc. affirmed the district court's judgment that the mutual release in the settlement…
Smart & Biggar | Canada | 4 Jan 2023
2022 Highlights in Canadian Life Sciences IP and Regulatory Law
The Federal Courts released the following patent decisions in 2022, all relating to s. 6(1) actions under the Patented Medicines (Notice of…
Pearce IP | Australia, European Union, USA | 19 Dec 2022
BioBlast w/e 16 Dec 22: Doer Biologics and Merck collaboration, expanded Dupixent® indications, Fresenius US citrate-free Idacio® (adalimumab) approval, Merck and Moderna cancer vaccine trial results, Amgen acquires Horizon, Alvotech lists on Nasdaq Iceland Main Market, Regeneron seeks expedited motion in aflibercept dispute
Zhejiang Doer Biologics announced a clinical trial collaboration agreement with Merck to evaluate DR30303 (humanized anti-Claudin18.2 heavy chain…
